India Starts Making Key API Clavulanic Acid

New Delhi: India has started producing blockbuster clavulanic acid for the first time in what could reduce its dependence on China for APIs. Mumbai-based Kinvan has started producing clavulanic acid that goes into making Augmentin, used to treat various bacterial infections, people in the know told ET.

Industry sources say the company has started producing small batches and will begin full scale production of 300 metric tons towards the end of this year.

Kinvan will invest 447.17 crore to build a 300 mt capacity plant to produce clavulanic acid.

Clavulanic acid also (key starting material) is used for manufacturing amoxyclav (combination of two medicines). Its most popular brand is Augmentin. “As of now we are largely dependent on China. With the initiative of the production-linked incentive scheme companies, we will see production of clavulanic acid and Penicillin G by the end of this year. Kinvan is in advanced stages and large scale fermentation is expected by the end of this year. It’s a step in the right direction,” a person in the know said.

Related Posts

Ayurveda needs stronger evidence, safety monitoring for market adoption, says CCRAS

Bengaluru: The Central Council for Research in Ayurvedic Sciences (CCRAS) has called for stronger scientific evidence, safety monitoring and translation of research into market-ready technologies to improve the credibility and…

Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

The Team Meticulously averted the Risk of Thrombosis, Husband was Donor Delhi/NCR : Doctors at Yashoda Medicity have successfully performed a high-risk kidney transplant in a 28-year-old woman with Antiphospholipid…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Ayurveda needs stronger evidence, safety monitoring for market adoption, says CCRAS

Ayurveda needs stronger evidence, safety monitoring for market adoption, says CCRAS

Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

US FDA approves first gene therapy for paediatric patients with Sanfilippo syndrome type A

US FDA approves first gene therapy for paediatric patients with Sanfilippo syndrome type A

Technology and accessibility are key to growth of advanced treatment of heart diseases, says expert

Technology and accessibility are key to growth of advanced treatment of heart diseases, says expert

Puresta launches EVERQ, AI-powered skin-health platform

Puresta launches EVERQ, AI-powered skin-health platform